CURONZ HOLDINGS COMPANY LTD has a total of 24 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2006. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are DIA B TECH LTD, METHERESIS TRANSLATIONAL RES SA and CENES PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Australia | 4 | |
#5 | New Zealand | 3 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Sieg Frank | 23 |
#2 | Brimble Margaret Anne | 6 |
#3 | Harris Paul William Richard | 6 |
#4 | Brimble Margaret Ann | 1 |
#5 | Muir Victoria Justine | 1 |
#6 | Frank Sieg | 1 |
Publication | Filing date | Title |
---|---|---|
WO2015194970A2 | Method of treating or preventing multiple sclerosis using one or more neural regeneration peptides | |
AU2014357818A1 | Method of treating or preventing epilepsy or seizures using one or more neural regeneration peptides | |
AU2014226650A1 | Neural regeneration peptides and uses therefor | |
US2016015771A1 | Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury | |
NZ625919A | Neural regeneration peptides and uses therefor | |
NZ617069A | Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury | |
WO2012102625A2 | Therapeutic composition | |
WO2012105854A2 | Compositions for administration to the eye | |
EP1888635A2 | Neural regeneration peptides and methods for their use |